scholarly journals Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor α and c-Myc

2009 ◽  
Vol 16 (3) ◽  
pp. 819-834 ◽  
Author(s):  
Maya Dadiani ◽  
Dalia Seger ◽  
Tamar Kreizman ◽  
Daria Badikhi ◽  
Raanan Margalit ◽  
...  

The role of c-Myc in estrogen regulation of vascular endothelial growth factor (VEGF) and of the vasculature function has been investigated in breast cancer cells and tumors. The studies were performed on MCF7 wild-type cells and MCF7-35im clone, stably transfected with an inducible c-Myc gene. In vitro and ex vivo methods for investigating molecular events were integrated with in vivo magnetic resonance imaging of the vascular function. The results showed that the c-Myc upregulation by estrogen is necessary for the transient induction of VEGF transcription; however, overexpression of c-Myc alone is not sufficient for this induction. Furthermore, both c-Myc and the activated estrogen receptor α (ERα) were shown to co-bind the VEGF promoter in close proximity, indicating a novel mechanism for estrogen regulation of VEGF. Studies of long-term estrogen treatment and overexpression of c-Myc alone demonstrated regulation of stable VEGF expression levels in vitro and in vivo, maintaining steady vascular permeability in tumors. However, withdrawal of estrogen from the tumors resulted in increased VEGF and elevated vascular permeability, presumably due to hypoxic conditions that were found to dominate VEGF overexpression in cultured cells. This work revealed a cooperative role for ERα and c-Myc in estrogen regulation of VEGF and the ability of c-Myc to partially mimic estrogen regulation of angiogenesis. It also illuminated the differences in estrogen regulation of VEGF during transient and long-term sustained treatments and under different microenvironmental conditions, providing a complementary picture of the in vitro and in vivo results.

2009 ◽  
Vol 62 (5) ◽  
pp. 474-476 ◽  
Author(s):  
E Amir ◽  
M Trinkaus ◽  
C E Simmons ◽  
G Dranitsaris ◽  
M J Clemons

Background:Recent data have shown a fall in vascular endothelial growth factor (VEGF) concentrations after bisphosphonate (BP) treatment in BP-naïve patients. It has therefore been proposed that BPs may have in vivo anti-VEGF effects.Aims:To explore whether VEGF concentrations change after administration of a more potent BP in patients receiving long-term BP treatment.Methods:31 patients with breast cancer who had progressive metastatic bone disease despite treatment with early-generation BPs were switched to zoledronic acid. Serum VEGF concentrations were measured at baseline, and weeks 1, 2, 3, 4, 8 and 12.Results:VEGF concentration per platelet count did not change significantly at any time during the 12 weeks after treatment with zoledronic acid.Conclusions:Switching to zoledronic acid did not suppress circulating serum VEGF concentrations in BP-pretreated patients. Novel approaches to assess the effect of BPs on the bone milieu may provide further insight into the possible antiangiogenic properties of BPs.


2013 ◽  
Vol 9 (1) ◽  
pp. 94 ◽  
Author(s):  
Arianna Aricò ◽  
Mery Giantin ◽  
Maria Elena Gelain ◽  
Fulvio Riondato ◽  
Stefano Comazzi ◽  
...  

2017 ◽  
Vol 68 (4) ◽  
pp. 326-329
Author(s):  
Piotr Barć ◽  
Tomasz Płonek ◽  
Dagmara Baczyńska ◽  
Artur Pupka ◽  
Wojciech Witkiewicz ◽  
...  

2003 ◽  
Vol 55 (2) ◽  
pp. 119-124 ◽  
Author(s):  
Michael D. Mueller ◽  
Elizabeth A. Pritts ◽  
Charles J. Zaloudek ◽  
Ekkehard Dreher ◽  
Robert N. Taylor

2015 ◽  
Vol 11 (5) ◽  
pp. 3405-3413 ◽  
Author(s):  
WEIWEI CAI ◽  
YUE LI ◽  
QINGQING YI ◽  
FENGSHAN XIE ◽  
BIN DU ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document